Allergan has completed the previously announced acquisition of US-based Chase Pharmaceuticals for $125m.

CPC-­201 is a lead compound of Chase and combination of the commonly prescribed acetylcholinesterase inhibitor (AChEI), donepezil, and the peripherally acting cholinergic blocker, solifenacin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AChEIs have been approved and are only modestly effective due to dose-limiting side effects, including diarrhoea, nausea and vomiting.

Allergan chief research and development officer David Nicholson said: "Alzheimer's disease is a neurodegenerative disease that represents a major and growing global public health problem, for which very few approved treatment options are available, and the societal cost is measured in hundreds of billions of dollars, so the need for improved treatment choices is paramount.

"We at Chase Pharmaceuticals are passionate about developing and bringing to physicians and their patients profoundly improved Alzheimer's disease treatments."

"This acquisition adds a new Phase III ready programme for Alzheimer's disease to our CNS portfolio and builds on our commitment to develop innovative approaches to improve the lives of millions of patients suffering from this devastating illness."

See Also:

During Phase II clinical trials, 29 out of 33 patients reached 40mg/d of donepezil and did not experience dose-limiting adverse events.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chase Pharmaceuticals CEO and president Douglas Ingram said: "We at Chase Pharmaceuticals are passionate about developing and bringing to physicians and their patients profoundly improved Alzheimer's disease treatments. 

“I am very excited that Allergan has recognised the strong clinical value of our development programmes and look forward to seeing Allergan apply its leading clinical development and regulatory expertise to bring these potential treatments forward for patients."

Chase recently completed an end of Phase II meeting with the Food and Drug Administration (FDA) and based on the feedback, Allergan proposes to advance CPC-201 into a single Phase III registration study next year.